Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Jun Zhang
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06120439CT.gov Comparing the QoR of PECS Block and GA in Breast-conserving Surgery With Sentinel Lymph Node Biopsy | — | Completed | — | — | — |
NCT05646862CT.gov A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy | — | Active Not Recruiting | — | — | — |
NCT05647642CT.gov The Effect of Premedication on Postoperative Pain and Anxiety in Breast Cancer Surgery | — | Unknown | — | — | — |
NCT04019834CT.gov Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy | — | Completed | — | — | — |
NCT03955939CT.gov A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | — | Completed | — | — | — |
NCT03084536CT.gov PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery | — | Completed | — | — | — |
NCT01945476CT.gov Effect of Midazolam Premedication Before Induction on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Surgery Due to Breast Cancer | — | Completed | — | — | — |
NCT01655225CT.gov A Study of LY3023414 in Participants With Advanced Cancer | — | Completed | — | — | — |
NCT00258050CT.gov To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Midazolam (this asset) | Jun Zhang | Approved | B · 63 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Midazolam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuralgia | — | P4 | BBB · 75 |
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 75 |
| Choledocholithiasis | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Midazolam in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/midazolam-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →